Cardiff Oncology names Leila Alland interim chief medical officer

Cardiff Oncology (CRDF) appointed Leila Alland, MD, as interim Chief Medical Officer. The company's Phase 2 trial for onvansertib in metastatic colorectal cancer shows median progression-free survival not yet reached. A Phase 3 study is planned for Q1 2027. Alland has extensive experience in oncology drug development.

Original reporting
Published Oct 27, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CRDF
Neutral
high confidence
Mentioned
$CRDF
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRDFNeutralLow
01

Why it matters

The leadership change is unlikely to cause immediate price movement; market attention remains on upcoming Phase 3 plans and trial data.

02

Market read

The announcement is a modest corporate update with limited trading relevance.

03

What to watch

Alland's experience at major pharma could improve trial execution, but no concrete milestones were announced.

Relevance 5/10Novelty 5/10Timing: today

Background

Cardiff Oncology is a clinical‑stage biotech focused on RAS‑mutated cancers with its PLK1 inhibitor onvansertib in Phase 2 trials.

Company-level read

Ticker impact

$CRDFNeutralHigh confidence
Context

Cardiff Oncology announced the appointment of Leila Alland as interim Chief Medical Officer, a new executive change for the company.

Expected impact

likely neutral as investors await further clinical data.

Evidence & confidence

Executive changes at early‑stage biotech rarely move the stock unless tied to a material milestone; no new trial results were disclosed.

Market effects

Minimal effect on the broader oncology biotech sector; the change does not signal new strategic direction.

No regional impact beyond the company's own share activity.

Limited global relevance; the news is company‑specific.

Counterpoint

If investors view the new CMO as a catalyst for accelerated trial progress, the stock could see upside.

Key entities

  • Leila Alland

    Appointed interim Chief Medical Officer of Cardiff Oncology.

  • Cardiff Oncology, Inc.

    Biotech developing PLK1 inhibitors for RAS‑mutated cancers.

Related articles

$CRDFHighAI 9/10

Why is Cardiff Oncology stock surging today?

Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.

$CRDFMed

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t

$CRDFMedAI 8/10

FDA grants orphan drug status to Cardiff’s onvansertib for CMML

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

$CRDFMed

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m